The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2152-2166

  Xie, G ^a   Nie, T ^a   MacKenzie, G G ^a   Sun, Y ^a   Huang, L ^a   Ouyang, N ^a   Alston, N ^a   Zhu, C ^a   Murray, O T ^a   Constantinides, P P ^b   Kopelovich, L ^c   Rigas, B ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Medicon Pharmaceuticals Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

difluoromethylornithine; gastrointestinal toxicity; liver microsomes; metabolism; pharmacokinetics; phospho sulindac

Indexed keywords

EFLORNITHINE; OXT 328; PHOSPHO SULINDAC; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOSOL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTESTINE MICROSOME; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOSOL; EFLORNITHINE; FEMALE; HUMANS; INTESTINES; MICE; MICE, INBRED BALB C; MICROSOMES; MICROSOMES, LIVER; ORGANOPHOSPHORUS COMPOUNDS; RATS; SULINDAC; TISSUE DISTRIBUTION;

EID: 84863257781     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01705.x     Document Type: Article

References (48)

1. Acosta EJ, Harwell JH, Sabatini DA, (2004). Self-assembly in linker-modified microemulsions. J Colloid Interface Sci 274: 652-664. (Pubitemid 38610339)
2. Anders MW, Ratnayake JH, Hanna PE, Fuchs JA, (1981). Thioredoxin- dependent sulfoxide reduction by rat renal cytosol. Drug Metab Dispos 9: 307-310. (Pubitemid 11057588)
3. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW, (2003). Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 278: 47762-47775. (Pubitemid 37523223)
4. Bajrami B, Zhao L, Schenkman JB, Rusling JF, (2009). Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format. Anal Chem 81: 9921-9929.
5. Baron JA, (2009). Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res 181: 223-229.
6. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al,. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507.
7. Davis PJ, Guenthner LE, (1985). Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism. Xenobiotica 15: 845-857. (Pubitemid 16223014)
8. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS, (1995). Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 345: 855-856.
9. DiSario JA, Alberts DS, Tietze CC, Khullar SK, Bohman VD, Larsen BR, et al,. (1997). Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastroenterology 112: A555.
10. Gao J, Kashfi K, Rigas B, (2005). In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther 312: 989-997. (Pubitemid 40293757)
11. Gerner EW, Meyskens FL Jr, (2004). Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 781-792. (Pubitemid 39331150)
12. Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D, (2007). Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 33: 189-195. (Pubitemid 47222961)
13. Glavin GB, Sitar DS, (1986). The effects of sulindac and its metabolites on acute stress-induced gastric ulcers in rats. Toxicol Appl Pharmacol 83: 386-389. (Pubitemid 16079423)
14. Gupta S, Moulik SP, (2008). Biocompatible microemulsions and their prospective uses in drug delivery. J Pharm Sci 97: 22-45.
15. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD, (2000). Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol 60: 7-17. (Pubitemid 30243080)
16. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al,. (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52: 237-245. (Pubitemid 26233752)
17. Hayase K, Tappel AL, (1969). Microsomal esterase of rat liver. J Biol Chem 244: 2269-2274.
18. Hosokawa M, (2008). Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13: 412-431.
19. Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, et al,. (2010). Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis 31: 1982-1990.
20. Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, et al,. (2011). The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 162: 1521-1533.
21. Kaimul AM, Nakamura H, Masutani H, Yodoi J, (2007). Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 43: 861-868. (Pubitemid 47223630)
22. Kashfi K, Rigas B, (2005). Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 33: (Pt 4): 724-727. (Pubitemid 41160850)
23. Kirschning A, Ries M, Domann S, Martin W, Albrecht W, Arnold P, et al,. (1997). Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000. Bioorg Med Chem Lett 7: 903-906. (Pubitemid 27154330)
24. Lamboursain L, St-Onge F, Jolicoeur M, (2002). A lab-built respirometer for plant and animal cell culture. Biotechnol Prog 18: 1377-1386. (Pubitemid 35450897)
25. Lanas A, Ferrandez A, (2009). NSAIDs and the colon. Curr Opin Gastroenterol 25: 44-49.
26. Leite S, Martins NM, Dorta DJ, Curti C, Uyemura SA, dos Santos AC, (2006). Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic Clin Pharmacol Toxicol 99: 294-299. (Pubitemid 44578905)
27. Liu D, Zheng X, Tang Y, Zi J, Nan Y, Wang S, et al,. (2010). Metabolism of tanshinol borneol ester in rat and human liver microsomes. Drug Metab Dispos 38: 1464-1470.
28. Ljungquist A, Augustinsson KB, (1971). Purification and properties of two carboxylesterases from rat-liver microsomes. Eur J Biochem 23: 303-313.
29. Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, et al,. (2010). Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139: 1320-1332.
30. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, et al,. (2011). Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in a mouse xenograft model. Cancer Prev Res (Phila) 4: 1052-1060.
31. Mantovani A, Allavena P, Sica A, Balkwill F, (2008). Cancer-related inflammation. Nature 454: 436-444.
32. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al,. (2008). Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1: 9-11.
33. Morishita Y, Fujii M, Kasakura Y, Takayama T, (2005). Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan. J Int Med Res 33: 84-89. (Pubitemid 40201940)
34. Nagy A, Plonowski A, Schally AV, (2000). Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci U S A 97: 829-834. (Pubitemid 30070395)
35. Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, et al,. (2009). A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila) 2: 572-580.
36. Ratnayake JH, Hanna PE, Anders MW, Duggan DE, (1981). Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes. Drug Metab Dispos 9: 85-87. (Pubitemid 11150854)
37. Rigas B, (2007). The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 23: 55-59. (Pubitemid 44875911)
38. Rigas B, Williams JL, (2008). NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19: 199-204.
39. Roberts J II, Morrow J, (2001). Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment gout. In:, Hardman JG, Limbird LE, (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. McGraw-Hill: New York, pp. 687-731.
40. Shiff SJ, Rigas B, (1999). The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs), [comment]. J Exp Med 190: 445-450. (Pubitemid 29395372)
41. Shiff SJ, Qiao L, Tsai LL, Rigas B, (1995). Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503.
42. Sostres C, Gargallo CJ, Arroyo MT, Lanas A, (2010). Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24: 121-132.
43. Steinbrink SD, Pergola C, Buhring U, George S, Metzner J, Fischer AS, et al,. (2010). Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 67: 797-806.
44. Taketani M, Shii M, Ohura K, Ninomiya S, Imai T, (2007). Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci 81: 924-932. (Pubitemid 47374212)
45. Wallace JL, (2008). Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88: 1547-1565.
46. Wallace JL, Vong L, (2008). NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. Curr Opin Investig Drugs 9: 1151-1156.
47. Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, et al,. (2011). Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337: 876-886.
48. Yarrington JT, Sprinkle DJ, Loudy DE, Diekema KA, McCann PP, Gibson JP, (1983). Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase. Exp Mol Pathol 39: 300-316. (Pubitemid 14208727)